Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: A study of 172 patients

Blood

Volumn 115, Issue 22, 2010, Pages 4350-4355

  Morel, Pierre ^a,b   Duhamel, Alain ^b   Hivert, Benedicte ^a   Stalniekiewicz, Laure ^a   Demory, Jean Loup ^c   Dupriez, Brigitte ^a,d  

^a Centre Hospitalier de LENS   (France)

^b UNIV LILLE   (France)

^c hôpital Saint Vincent   (France)

^d UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOID METAPLASIA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SPLENECTOMY; THROMBOCYTOPENIA; BLAST CELL CRISIS; FRANCE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME;

ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKOCYTOSIS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS;

EID: 77953923573     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-255943     Document Type: Article

References (34)

1. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17(9):2954-2970.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255-1265.
3. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997;98(1):96-102.
4. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013-1018.
5. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
6. Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009;113(18):4171-4178.
7. Stein RS. Relevance of prognostic features in myeloid metaplasia to selection of patients for bone marrow transplantation. Blood. 1997;89(6):2219-2220.
8. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102(3):684-690.
9. Morel P, Duhamel A. Comparison of prognostic scoring systems in primary myelofibrosis [letter]. Blood. 2010;115(3):745.
10. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111(7):3383-3387.
11. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-5593.
12. Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2009;114(26):5264-5270.
13. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;117(2):288-296.
14. Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia: a pilot study. Leukemia. 2002;16(9):1609-1614.
15. Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114(1):78-83.
16. Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002;99(10):3854-3856.
17. Verstovsek S. JAK2 inhibitors and myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2008;6(12):878-880, 896.
18. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
19. Chelloul N, Briere J, Laval-Jeantet M, Najean Y, Vorhauer W, Jacquillat C. Prognosis of myeloid metaplasia with myelofibrosis. Biomedicine. 1976;24(4):272-280.
20. ISCN. An international system for human cytogenetic nomenclature. Cytogenet Cell Genet. 1978;21:309.
21. Crowley J, Hu M. Covariance analysis of heart transplant survival data. J Am Stat Assoc. 1977;72:72-76.
22. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000.
23. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737-740.
24. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distribution. J Am Stat Assoc. 1989;84:1065-1073.
25. Beyersmann J, Schumacher M. Time-dependent covariates in the proportional subdistribution hazards model for competing risks. Biostatistics. 2008;9(4):765-776.
26. Anderson JR, Cain KC, Geller RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710-719.
27. Passamonti F, Cervantes F, Vannucchi A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT). Blood. 2010;115(9):1703-1708.
28. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98(12):3249-3255.
29. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112(12):2726-2732.
30. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia: Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood. 1998;91(10):3630-3636.
31. Wolkewitz M, Vonberg RP, Grundmann H, et al. Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. Crit Care. 2008;12(2):R44.
32. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood. 2001;97(6):1896. (Pubitemid 32217264)
33. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93(9):2831-2838.
34. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reducedintensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99(6):2255-2258.